Synonyms: BTZ-10526043 | MMV676603
Compound class:
Synthetic organic
Comment: BTZ-043 is the lead from a novel class of benzothiazinone compounds with antimycobacterial activity [1], that is is under clinical evaluated as a treatment for tuberculosis (TB). It is an inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme [1-3].
|
|
References |
1. Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP et al.. (2009)
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science, 324 (5928): 801-4. [PMID:19299584] |
2. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Röttger S, Buroni S, Fullam E, Degiacomi G, Lucarelli AP et al.. (2012)
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med, 4 (150): 150ra121. [PMID:22956199] |
3. Trefzer C, Škovierová H, Buroni S, Bobovská A, Nenci S, Molteni E, Pojer F, Pasca MR, Makarov V, Cole ST et al.. (2012)
Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1. J Am Chem Soc, 134 (2): 912-5. [PMID:22188377] |